A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma

Trial Profile

A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Pidilizumab (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 16 Jun 2016 Preliminary data were presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO) 2016, according to a Medivation media release.
    • 16 Jun 2016 Interim results (n=9) published in a Medivation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top